1
|
Hu M, Li X, Wang L, Zhang Y, Sun Y, Hua H, Liu H, Cai T, Zhu D, Xiang Q. ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells. ACS Med Chem Lett 2024; 15:406-412. [PMID: 38505849 PMCID: PMC10945796 DOI: 10.1021/acsmedchemlett.3c00571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/09/2024] [Accepted: 02/12/2024] [Indexed: 03/21/2024] Open
Abstract
Ferroptosis is a novel form of oxidative cell death triggered by iron-dependent lipid peroxidation. The induction of ferroptosis presents an attractive therapeutic strategy for human diseases, such as prostate cancer and breast cancer. Herein, we describe our design, synthesis, and biological evaluation of endogenous glutathione peroxidase 4 (GPX4) degraders using the proteolysis targeting chimera (PROTAC) approach with the aim of inducing ferroptosis in cancer cells. Our efforts led to the discovery of compound 5i (ZX703), which significantly degraded GPX4 through the ubiquitin-proteasome and the autophagy-lysosome pathways in a dose- and time-dependent manner. Moreover, 5i was found to induce the accumulation of lipid reactive oxygen species (ROS) in HT1080 cells, thereby inducing ferroptosis. This study provides an attractive intervention strategy for ferroptosis-related diseases.
Collapse
Affiliation(s)
- Mengdie Hu
- Department
of Urology, The Second Affiliated Hospital of Nanjing Medical University,
and Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China
| | - Xiaomei Li
- Guoke
Ningbo Life Science and Health Industry Research Institute, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315000, China
| | - Lin Wang
- Department
of Urology, The Second Affiliated Hospital of Nanjing Medical University,
and Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China
| | - Yanping Zhang
- Department
of Urology, The Second Affiliated Hospital of Nanjing Medical University,
and Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China
| | - Yujie Sun
- Guoke
Ningbo Life Science and Health Industry Research Institute, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315000, China
| | - Hui Hua
- Guoke
Ningbo Life Science and Health Industry Research Institute, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315000, China
| | - Huina Liu
- Guoke
Ningbo Life Science and Health Industry Research Institute, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315000, China
| | - Ting Cai
- Guoke
Ningbo Life Science and Health Industry Research Institute, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315000, China
| | - Dongsheng Zhu
- Department
of Urology, The Second Affiliated Hospital of Nanjing Medical University,
and Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China
| | - Qiuping Xiang
- Guoke
Ningbo Life Science and Health Industry Research Institute, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315000, China
| |
Collapse
|